We therefore cannot rule out the possibility that some colocalization findings suggesting low posterior probabilities of shared causal variants across traits (e.g., colocalization analyses for genetically proxied NCC inhibition and ER− breast cancer risk) reflected the limited power of this approach. This evidence concerns the gene SLC12A3 and breast cancer.